Cytolytic syndrome associated with the treatment for COVID-19
Author:
Open Access
- 30 June 2021
- journal article
- research article
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 140-146
Abstract
The article describes a clinical case of an increased level of hepatic transaminases during a delayed period of the treatment in a patient with coronavirus disease COVID-19 using remdesivir and a possible effect of hepatic steatosis on the severity of cytolytic syndrome associated with the course of COVID-19.Keywords
This publication has 7 references indexed in Scilit:
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsNew England Journal of Medicine, 2021
- Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network StudyGastroenterology, 2020
- Extrapulmonary manifestations of COVID-19Nature Medicine, 2020
- Compassionate Use of Remdesivir in Covid-19New England Journal of Medicine, 2020
- Delayed Initiation of Remdesivir in a COVID‐19‐Positive PatientPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Liver injury in COVID-19: management and challengesThe Lancet Gastroenterology & Hepatology, 2020
- Characteristics and Mechanism of Liver Injury in 2019 Coronavirus DiseaseJournal of Clinical and Translational Hepatology, 2020